F. Zoulim

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
F Zoulim, F. Zoulim, Fabien Zoulim
Publication record
814 papers · 46,939 citations · H-index 108

PAPERS

A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
202328 citationsauthor #10
Intrahepatic hepatitis B virus cccDNA amount and transcriptional activity in a well-characterized cohort of Gambian chronically infected patients: correlation with emerging serum viral markers
20230 citationsauthor #8
Evaluation of the hepatitis B virus liver reservoir with fine needle aspirates
20230 citationsauthor #12
The TLR8 agonist Selgantolimod modulates Kupffer cell differentiation status and indirectly impairs HBV entry into hepatocytes via an IL-6-dependent mechanism
20230 citationsauthor #10
Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis
202314 citationsauthor #17
Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation
20232 citationsauthor #17
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
202330 citationsauthor #38
Treatment with Bulevirtide, with or without PEG-interferon, in HIV-HBV/HDV co-infected patients in a real-life setting
20230 citationsauthor #21
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022
202327 citationsauthor #7
Kinetics of hepatitis B core related antigen in patients with compensated HDV cirrhosis treated with Bulevirtide monotherapy for 72 weeks: a single-center study
20231 citationsauthor #15
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
202338 citationsauthor #5
Prevalence of diagnosed advanced liver fibrosis in high-risk population with metabolic-dysfunction associated fatty liver disease screened in diabetology using transient elastography
20230 citationsauthor #7
Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
202324 citationsauthor #1
Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study.
20237 citationsauthor #4
The Hepatitis B Virus Genotypes E to J: The Overlooked Genotypes
202313 citationsauthor #4
New perspectives on development of curative strategies for chronic hepatitis B.
202341 citationsauthor #3
The performance of the cobas® HBV RNA assay for use on the cobas® 5800/6800/8800 Systems (RUO) against genomic variants and transcript heterogeneity
20230 citationsauthor #13
Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
20230 citationsauthor #13
Low HBV DNA and HBsAg levels at 24 weeks off-treatment predict sustained response and HBsAg loss in patients who discontinued antiviral therapy
20230 citationsauthor #13
HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
20232 citationsauthor #27
Assessment of neutrophil subsets and immune checkpoint inhibitor expressions on T lymphocytes in liver transplantation: A preliminary study beyond the neutrophil-lymphocyte ratio
20233 citationsauthor #9
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study
20238 citationsauthor #13
The scientific basis of combination therapy for chronic hepatitis B functional cure
2023123 citationsauthor #9
Evaluation of the HBV liver reservoir with fine needle aspirates
202318 citationsauthor #12
Emerging anti‐HDV drugs and HBV cure strategies with anti‐HDV activity
20239 citationsauthor #6
Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics
20231 citationsauthor #6
Long-term trends of circulating hepatitis B virus RNA and hepatitis B core-related antigen levels in persons with HIV and functional hepatitis B cure during tenofovir therapy
20230 citationsauthor #14
A sequential use of transient elastography followed by Agile 3+ score significantly improves the screening of advanced fibrosis in patients with NAFLD with or without severe obesity
20230 citationsauthor #7
Interspecies comparison of the early transcriptomic changes associated with hepatitis B virus exposure in human and macaque immune cell populations
20230 citationsauthor #19
Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study
20230 citationsauthor #6
Heparanase-1: From Cancer Biology to a Future Antiviral Target
20235 citationsauthor #2
Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
202327 citationsauthor #21
Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure
202361 citationsauthor #13
Circulating microRNAs improve bacterial infection diagnosis and overall survival prediction in acute decompensation of liver cirrhosis
20233 citationsauthor #15
Axon guidance molecules in liver pathology: Journeys on a damaged passport
20234 citationsauthor #4
Improved hepatitis delta virus genome characterization by single molecule full‐length genome sequencing combined with VIRiONT pipeline
20239 citationsauthor #6
Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)
20235 citationsauthor #13
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors
20228 citationsauthor #20
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
202293 citationsauthor #12
Comprehensive immunophenotyping reveals profound alterations of T cell subsets in acute decompensation of liver cirrhosis
20220 citationsauthor #12
Gene Editing Technologies to Target HBV cccDNA
202229 citationsauthor #5
Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.
202214 citationsauthor #9
A persistent HBV infection features spontaneous cccDNA loss and new rounds of infection
20220 citationsauthor #4
Nomenclature of HBV core protein-targeting antivirals
202249 citationsauthor #1
Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension
20220 citationsauthor #13
Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels
20220 citationsauthor #12
Heparanase is upregulated by HCV and favors its replication.
202210 citationsauthor #9
Cannabis Use Is Inversely Associated with Metabolic Disorders in Hepatitis C-Infected Patients (ANRS CO22 Hepather Cohort)
20224 citationsauthor #11
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
2022136 citationsauthor #28
HIRA Supports Hepatitis B Virus Minichromosome Establishment and Transcriptional Activity in Infected Hepatocytes
202220 citationsauthor #13
Significance of serum HBV RNA in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients who discontinue effective antiviral therapy
202216 citationsauthor #14
Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide
20220 citationsauthor #12
Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort).
202219 citationsauthor #11
Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort
20228 citationsauthor #22
Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis.
202259 citationsauthor #21
Off-therapy cure of hepatitis delta after 3 years of bulevirtide monotherapy in a patient with compensated advanced cirrhosis
20223 citationsauthor #13
Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients
20220 citationsauthor #14
CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants
202237 citationsauthor #11
Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection
202213 citationsauthor #6
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
20221 citationsauthor #6
Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes
202220 citationsauthor #13
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
20222 citationsauthor #5
Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study
20222 citationsauthor #13
Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease
202215 citationsauthor #11
Hepatic inflammation elicits production of proinflammatory netrin‐1 through exclusive activation of translation
202215 citationsauthor #24
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort
20221 citationsauthor #20
Hepatocellular carcinoma hosts immature neurons and cholinergic tumors that correlate with adverse molecular features and outcomes
20222 citationsauthor #13
Sequence characterization of extracellular HBV RNA in patient plasma
20222 citationsauthor #7
Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
20226 citationsauthor #14
Copper Isotope Evidence of Oxidative Stress–Induced Hepatic Breakdown and the Transition to Hepatocellular Carcinoma
20225 citationsauthor #4
Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008–2012: A cross-sectional study
202212 citationsauthor #5
Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients
20220 citationsauthor #11
Viral hepatitis Elimination: Towards a hepatitis free world.
202210 citationsauthor #7
Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection
20217 citationsauthor #11
An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
20210 citationsauthor #4
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
20216 citationsauthor #7
Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity in vitro
202113 citationsauthor #12
Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
20211 citationsauthor #6
HBV 2021: New therapeutic strategies against an old foe
202143 citationsauthor #3
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.
202113 citationsauthor #7
HCV Virology
20211 citationsauthor #2
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis
202115 citationsauthor #6
Molecular Crosstalk between the Hepatitis C Virus and the Extracellular Matrix in Liver Fibrogenesis and Early Carcinogenesis
202116 citationsauthor #3
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation
202151 citationsauthor #17
Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
202144 citationsauthor #22
Hepatitis B virus genome diversity in adolescents: Tenofovir disoproxil fumarate treatment effect and HBeAg serocon version
20213 citationsauthor #9
Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts
20216 citationsauthor #10
Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
2021110 citationsauthor #5
Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis
202129 citationsauthor #15
External validation of the French alpha‐fetoprotein model for hepatocellular carcinoma liver transplantation in a recent unicentric cohort – a retrospective study
20212 citationsauthor #8
Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)
20214 citationsauthor #8
Hepatitis B Virus Genotype Study in West Africa Reveals an Expanding Clade of Subgenotype A4
20218 citationsauthor #8
Landscape of oncoviral genotype and co-infection via human papilloma and hepatitis B viral tumor in situ profiling
20219 citationsauthor #2
Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance
202118 citationsauthor #40
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B.
202110 citationsauthor #23
Molecular Virology and Life Cycle of Hepatitis B Virus
20211 citationsauthor #4
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
202156 citationsauthor #17
Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study
202110 citationsauthor #9
HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management
20212 citationsauthor #10
Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.
20204 citationsauthor #4

TIMELINE

1989 3 citations

1990 160 citations

1991 304 citations

1992 69 citations

1993 25 citations

1994 750 citations

1995 43 citations

1996 225 citations

1997 92 citations

1998 190 citations

1999 252 citations

2000 1,785 citations

2001 531 citations

2002 596 citations

2003 1,224 citations

2004 1,714 citations

2005 1,144 citations

2006 1,185 citations

2007 2,431 citations

2008 2,195 citations

2009 3,529 citations

2010 1,190 citations

2011 1,837 citations

2012 1,541 citations

2013 1,980 citations

2014 2,385 citations

2015 2,346 citations

2016 1,579 citations

2017 6,823 citations

2018 1,529 citations

2019 3,559 citations

2020 1,214 citations

2021 478 citations

2022 611 citations

2023 503 citations

Unknown 0 citations

F. Zoulim

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT